Shuttle Pharmaceuticals Holdings, Inc. - SHPH Company Long-Term Liabilities
The development of Shuttle Pharmaceuticals (SHPH) is independent of the economy and instead relies on the results of small molecule tests designed to enhance radiation therapy. Meanwhile, stable demand for medications is offset by sanction risks in supply chains and the complexities of foreign certification. This chart of current stock quotes on GURU.Markets captures the 0.00 metric, while the business minimizes costs by outsourcing production and testing to external contractors.
&width=1200&height=400&colorIndex=0&v=mvrk6wqv.ssk-7as46ww&start=20220704&end=20261028&filename=GURU_Markets_-_SHPH_-_Shuttle-Pharmaceuticals_-_Company-Long-Term-Debts "Shuttle Pharmaceuticals (SHPH) - Long-Term Debt from 04/28/2023 to 10/28/2026 | 👁️GURU.Markets👁️")
Summary analytical data breakdowns for Shuttle Pharma (SHPH)
Shuttle Pharmaceuticals (SHPH) maintains significant pricing power due to inelastic demand for its unique radio-oncology sensitizers. The analyzed volume of liabilities with a maturity exceeding one year reflects the business's long-term debt load. A decrease in this metric indicates strengthening financial stability on the balance sheet. However, an excessive reduction in liquidity could limit the development of innovative drugs. The trend in the firm's long-term borrowed funds allows for an assessment of the issuer's investment potential.